Basket | Login | Register


WP3: Development and validation of translatable pharmacodynamic markers (clinical studies)

Work Packages

Pharmacog Logo

Main Objectives

  • To evaluate the effect of AD treatments on the PharmaCog biomarker battery in both healthy volunteers and AD patients to determine sensitive markers of clinical pharmacology and support dose selection studies.
  • To establish mathematical models that describe the relationship between drug exposure and pharmacodynamic marker response and between responses in HVT and patients in order to support future clinical study design
  • Back-translate data generated to parallel pre-clinical studies (WP4) to identify those biomarkers with translational capacity to improve the predictive capacity of pre-clinical models

WP Leads

Academic Lead: Pr Régis Bordet (University of Lille, France) and Dr Pierre Payoux (INSERM, Toulouse)

WP Partners

  • UnivMed, France
  • University of Lille, France
  • INSERM, France
  • University of Foggia, Italy
  • Qualissima
  • Eisai Ltd



Last Updated: Tuesday 26 April 2011


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations